NCT04863287View on ClinicalTrials.gov

First Clinical Study of the Safety and Blood Levels of a Human Monoclonal Antibody (2217LS) Against Lyme Disease Bacteria in Healthy People

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 11, 2021

Primary Completion Date

August 16, 2022

Study Completion Date

August 16, 2022

Conditions
Lyme Disease
Interventions
BIOLOGICAL

2217LS

Fully Human Monoclonal Antibody

OTHER

0.9% Sodium Chloride (NaCl)

Subcutaneous injection

Trial Locations (1)

68502

Celerion Inc., Lincoln

Sponsors

Lead Sponsor

MassBiologics

Collaborators (1)

Celerion
All Listed Sponsors
collaborator

Celerion

INDUSTRY

lead

MassBiologics

OTHER